154 results on '"Labianca R."'
Search Results
2. PB0709 Thrombin Generation (TG) and D-Dimer Significantly Predict Early-Disease Recurrence (E-DR) in High-Risk Breast Cancer
3. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
4. 445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state
5. PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer
6. 391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials
7. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
8. PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy
9. Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
10. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
11. 399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial
12. Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis
13. A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial
14. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials
15. Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis
16. Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM)
17. Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial
18. Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial
19. The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
20. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
21. Thrombin generation predicts for early recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: results from the HYPERCAN study.
22. Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study
23. Correction to: Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial
24. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.
25. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
26. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
27. FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
28. Thrombin generation (TG) and D-dimer levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study
29. Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial
30. Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial
31. Thrombin generation for prediction of early cancer recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: data from the prospective HYPERCAN study
32. Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients
33. Sidedness influences prognosis in stage III but not in stage II colon cancer patients receiving an adjuvant therapy: A GISCAD analysis from three randomized trials including 5234 patients
34. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
35. FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
36. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
37. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
38. OC-1a: A prospective study of hemostatic biomarkers to predict early recurrence in high-risk breast cancer women undergoing post-surgical adjuvant systemic therapy
39. Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial
40. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)
41. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)
42. Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial
43. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
44. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
45. “Green oncology”: a new paradigm for medical oncology
46. Circulating microRNAs (miRNAs): Biomarkers for Lung Cancer
47. Cancer Registries Underestimate both the Type of Disease and also Number of Cases due to Pollution
48. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
49. A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab
50. Multidisciplinary management of prostate cancer patients: the PerSTEP data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.